Skip to main content

Table 5 Trial sponsor for repurposed agents by phase of drug development (as of February 27, 2020)

From: Repurposed agents in the Alzheimer’s disease drug development pipeline

Sponsor Phase I Phase II Phase III Total (%)
Academic Medical Centers 6 14 4 24 (45.3)
Biopharma 0 2 3 5 (9.4)
NIH 1 0 0 1 (1.9)
NIH and Academic Medical Centers 0 4 2 6 (11.3)
NIH and consortium 0 1 0 1 (1.9)
NIH and Industry 0 0 1 1 (1.9)
Academic Medical Centers and Industry 0 2 0 2 (3.8)
Academic Medical Centers and Foundation 1 4 0 5 (9.4)
Academic Medical Centers, Industry, and NIH 0 0 1 1 (1.9)
Other combinations 1 4 0 5 (9.4)
Other federal sources 0 1 1 2 (3.8)
Total 9 32 12 53 (100.0)
  1. Abbreviations: NIH National Institutes of Health